Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation

Pharmacogenomics Journal

Volumn 12, Issue 1, 2012, Pages 86-92

  Leventhal, A M ^a   David, S P ^b   Brightman, M ^a   Strong, D ^c   McGeary, J E ^c   Brown, R A ^c   Lloyd Richardson, E E ^d   Munafo M ^e   Uhl, G R ^f   Niaura, R ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g American Legacy Foundation   (United States)

Author keywords

bupropion Introduction; DRD4; smoking cessation; VNTR

Indexed keywords

AMFEBUTAMONE; DOPAMINE 4 RECEPTOR; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE INTERACTION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

ADULT; BUPROPION; CROSS-SECTIONAL STUDIES; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, DOPAMINE D4; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84856229702     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.64     Document Type: Article

References (43)

1. McGeary J. The DRD4 exon 3 VNTR polymorphism and addictionrelated phenotypes: a review. Pharmacol Biochem Behav 2009; 93: 222-229.
2. Wang E, Ding YC, Flodman P, Kidd JR, Kidd KK, Grady DL et al. The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet 2004; 74: 931-944. (Pubitemid 38568966)
3. David SP, Munafo MR, Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008; 8: 122-128. (Pubitemid 351411548)
4. Munafo MR, Clark TG, Moore LR, Payne E, Walton R, Flint J. Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol Psychiatry 2003; 8: 471-484. (Pubitemid 36829689)
5. Munafo MR, Johnstone EC. Smoking status moderates the association of the dopamine D4 receptor (DRD4) gene VNTR polymorphism with selective processing of smoking-related cues. Addict Biol 2008; 13: 435-439.
6. Munafo MR, Yalcin B, Willis-Owen SA, Flint J. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data. Biol Psychiatry 2008; 63: 197-206. (Pubitemid 350299323)
7. Asghari V, Schoots O, van Kats S, Ohara K, Jovanovic V, Guan HC et al. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol Pharmacol 1994; 46: 364-373. (Pubitemid 24271434)
8. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157-1165.
9. Van Tol HH, Wu CM, Guan HC, Ohara K, Bunzow JR, Civelli O et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-152.
10. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-614. (Pubitemid 21912282)
11. Rivera A, Cuellar B, Giron FJ, Grandy DK, de la Calle A, Moratalla R. Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem 2002; 80: 219-229. (Pubitemid 34809367)
12. Tarazi FI, Campbell A, Yeghiayan SK, Baldessarini RJ. Localization of dopamine receptor subtypes in corpus striatum and nucleus accumbens septi of rat brain: comparison of D1-, D2-, and D4-like receptors. Neuroscience 1998; 83: 169-176. (Pubitemid 28068047)
13. Mulcrone J, Kerwin RW. The regional pattern of D4 gene expression in human brain. Neurosci Lett 1997; 234: 147-150. (Pubitemid 27452114)
14. Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Conley RR et al. Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a [3H]NGD-94-1 study. Mol Psychiatry 1998; 3: 528-533.
15. Laucht M, Becker K, Blomeyer D, Schmidt MH. Novelty seeking involved in mediating the association between the dopamine D4 receptor gene exon III polymorphism and heavy drinking in male adolescents: results from a high-risk community sample. Biol Psychiatry 2007; 61: 87-92. (Pubitemid 44855746)
16. Ray LA, Bryan A, Mackillop J, McGeary J, Hesterberg K, Hutchison KE. The dopamine D receptor (DRD4) gene exon III polymorphism, problematic alcohol use and novelty seeking: direct and mediated genetic effects. Addict Biol 2009; 14: 238-244.
17. Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda Jr R, McGeary JE et al. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 2008; 32: 58-66. (Pubitemid 350293891)
18. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L et al. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 2003; 28: 1882-1888. (Pubitemid 41070854)
19. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE. Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res 2008; 32: 1113-1123.
20. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda Jr R. Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 2006; 30: 1288-1296. (Pubitemid 44114679)
21. McClernon FJ, Hutchison KE, Rose JE, Kozink RV. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology (Berl) 2007; 194: 433-441. (Pubitemid 47492991)
22. Laucht M, Becker K, Frank J, Schmidt MH, Esser G, Treutlein J et al. Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatry 2008; 47: 673-681.
23. Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 1998; 7: 453-458. (Pubitemid 28354105)
24. Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
25. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999; 288: 88-92. (Pubitemid 29113477)
26. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafo MR et al. Pharmacogenetic clinical trial of sustainedrelease bupropion for smoking cessation. Nicotine Tob Res 2007; 9: 821-833. (Pubitemid 47190150)
27. David SP, Strong DR, Munafo MR, Brown RA, Lloyd-Richardson EE, Wileyto PE et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007; 9: 1251-1257. (Pubitemid 350215057)
28. Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systemsbased candidate gene study of smoking cessation. Hum Mol Genet 2008; 17: 2834-2848.
29. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry 2008; 65: 683-693. (Pubitemid 351787239)
30. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2007; 9: 721-730. (Pubitemid 47009227)
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th edn. American Psychiatric Association: Washington, DC, 1994.
32. Lerman C, Caporaso NE, Audrain J, Main D, Bowman ED, Lockshin B et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 1999; 18: 14-20. (Pubitemid 29047355)
33. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767-773. (Pubitemid 23197523)
34. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
35. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström K-O. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 1991; 86: 1119-1127.
36. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004: CD000031.
37. Hall SM, Delucchi KL, Velicer WF, Kahler CW, Ranger-Moore J, Hedeker D et al. Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome. Nicotine Tob Res 2001; 3: 193-202. (Pubitemid 32821648)
38. Berrettini WH, Wileyto EP, Epstein L, Restine S, Hawk L, Shields P et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007; 61: 111-118. (Pubitemid 44855744)
39. Simpson J, Vetuz G, Wilson M, Brookes KJ, Kent L. The DRD4 receptor exon 3 VNTR and 50 SNP variants and mRNA expression in human postmortem brain tissue. Am J Med Genet B Neuropsychiatr Genet (in press).
40. Schoots O, Van Tol HH. The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J 2003; 3: 343-348. (Pubitemid 38072172)
41. Hutchison KE, LaChance H, Niaura R, Bryan A, Smolen A. The DRD4 VNTR polymorphism influences reactivity to smoking cues. J Abnorm Psychol 2002; 111: 134-143. (Pubitemid 34154877)
42. Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S et al. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res 2004; 130: 269-281. (Pubitemid 38595428)
43. Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat 2009; 36: 235-243.